Transcend Capital Advisors LLC Makes New Investment in Illumina, Inc. $ILMN

Transcend Capital Advisors LLC bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 2,352 shares of the life sciences company’s stock, valued at approximately $224,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Rise Advisors LLC lifted its stake in Illumina by 173.6% in the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 224 shares in the last quarter. Cullen Frost Bankers Inc. purchased a new stake in Illumina in the 2nd quarter worth approximately $41,000. Caitong International Asset Management Co. Ltd lifted its stake in Illumina by 2,936.8% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock worth $46,000 after purchasing an additional 558 shares in the last quarter. WPG Advisers LLC purchased a new stake in Illumina in the 1st quarter worth approximately $58,000. Finally, Blue Trust Inc. lifted its stake in Illumina by 63.1% in the 2nd quarter. Blue Trust Inc. now owns 654 shares of the life sciences company’s stock worth $62,000 after purchasing an additional 253 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Up 4.2%

NASDAQ:ILMN opened at $99.01 on Friday. The company has a fifty day moving average of $97.97 and a 200 day moving average of $92.30. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $15.22 billion, a P/E ratio of 12.53, a P/E/G ratio of 2.34 and a beta of 1.40.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the business posted $1.14 EPS. The firm’s revenue was up .4% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of Illumina in a research report on Wednesday, October 8th. Barclays lifted their target price on shares of Illumina from $90.00 to $95.00 and gave the company an “underweight” rating in a research report on Thursday, October 2nd. Evercore ISI dropped their target price on shares of Illumina from $135.00 to $132.00 and set an “outperform” rating for the company in a research report on Tuesday, October 7th. Citigroup lowered shares of Illumina from a “hold” rating to a “strong sell” rating and dropped their target price for the company from $85.00 to $80.00 in a research report on Wednesday, July 9th. Finally, Daiwa Capital Markets lowered shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 target price for the company. in a research report on Tuesday, August 12th. Five equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Illumina presently has an average rating of “Hold” and a consensus price target of $115.25.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.